SUBSCRIBE
SUBSCRIBE

TG Therapeutics, Inc.

NEWS
Press Releases
TG Therapeutics Reports Second Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance
August 6, 2024
 · 
20 min read
Press Releases
TG Therapeutics to Host Conference Call on Second Quarter 2024 Financial Results and Business Update
August 5, 2024
 · 
1 min read
Pharm Country
TG Therapeutics to Participate in the Jefferies Global Healthcare ConferenceFireside chat scheduled for Wednesday, June 5, 2024, at 1:30 PM ET
June 3, 2024
 · 
1 min read
Pharm Country
TG Therapeutics Announces Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting
May 31, 2024
 · 
13 min read
Pharm Country
TG Therapeutics Announces Schedule of Upcoming Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting
May 28, 2024
 · 
14 min read
Business
TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
May 1, 2024
 · 
19 min read
Business
TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business Update
April 30, 2024
 · 
1 min read
Drug Development
TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
April 18, 2024
 · 
13 min read
Business
TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis
April 18, 2024
 · 
13 min read
Pharm Country
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
April 15, 2024
 · 
14 min read
Pharm Country
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
March 8, 2024
 · 
14 min read
Drug Development
TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
March 1, 2024
 · 
13 min read
Business
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results
February 28, 2024
 · 
20 min read
Pharm Country
TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy)Newly issued patents extend exclusivity of ublituximab through 2042
February 27, 2024
 · 
15 min read
Pharm Country
TG Therapeutics Announces European Launch of BRIUMVI® (ublituximab-xiiy)Ex-US partner, Neuraxpharm, launches BRIUMVI in Germany, the first European country
February 26, 2024
 · 
13 min read
Business
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business UpdateConference call to be held Wednesday, February 28, 2024, at 8:30 AM ET
February 23, 2024
 · 
1 min read
Load More
AWARDS
  • 2026 - Best Places to Work - Badge (1).png
JOBS